[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
chevron_left

ASH 2022

1. Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022 Video

bookmark_border

2. Individualized Prediction Model in Myeloma & Genome Sequencing | Francesco Maura, MD | ASH 2022 Video

bookmark_border

3. MODAKAFUSP ALFA (TAK-573) | Dan Vogl, MD, MSCE | ASH 2022 Video

bookmark_border

4. Opioid Use in Managing Pain in Myeloma | Karen Sweiss, PharmD | ASH 2022 Video

bookmark_border

5. Frailty and Multiple Myeloma | Hira Mian, MD, MSc | ASH 2022 Video

bookmark_border

6. MajesTEC-2 Trial | Emma Searle, MBChB MA MRCP FRCPath PhD | ASH 2022 Video

bookmark_border

7. Barriers to Participation in Hematology Trials | Shakira Grant, MBBS & Jiona Mills | ASH 2022 Video

bookmark_border
adjust

8. Talquetamab | Ajai Chari, MD | ASH 2022 Video

bookmark_border

9. OPTIMUM MUK Nine Trial | Martin Kaiser, MD | ASH 2022 Video

bookmark_border

10. How to Better Diagnose Patients With High-Risk Myeloma | Martin Kaiser, MD | ASH 2022 Video

bookmark_border

11. Waitlists for CAR-T | Samer Al'Hadidi, MD | ASH 2022 Video

bookmark_border

12. The Need For New Clinical Trial Strategies | Hearn J. Cho, MD | ASH 2022 Video

bookmark_border

13. Advancements in Immunotherapy Agents | Hearn J. Cho, MD | ASH 2022 Video

bookmark_border

14. Nutrivention Trials | Urvi Shah, MD | ASH 2022 Video

bookmark_border

15. Building a Dietary Evidence Symposium | Urvi Shah, MD | ASH 2022 Video

bookmark_border

16. T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022 Video

bookmark_border

17. Bispecifics | Urvi Shah, MD | ASH 2022 Video

bookmark_border

18. CAR-T Therapy | Santiago Thibaud, MD | ASH 2022 Video

bookmark_border

19. CAR-T BMS-986354 | Luciano Costa, MD, PhD | ASH 2022 Video

bookmark_border

20. Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022 Video

bookmark_border

21. Effect of a Covid Infection in Patients Prior to Transplant | Meera Mohan, MD, MS, FACP | ASH 2022 Video

bookmark_border

22. New Developments at ASH | Rafat Abonour, MD | ASH 2022 Video

bookmark_border

23. Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022 Video

bookmark_border

24. Patient Top Concerns at and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022 Video

bookmark_border

25. Bispecific T Cell Engagers | Noopur Raje, MD | ASH 2022 Video

bookmark_border

26. Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022 Video

bookmark_border

27. MRD Detection in Blood | Bruno Paiva, PhD | ASH 2022 Video

bookmark_border

28. iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022 Video

bookmark_border

29. Post BCMA Therapy | Gurbakhash Kaur, MD | ASH 2022 Video

bookmark_border

30. LINKER-MM1 Study in RRMM | Naresh Bumma, MD | ASH 2022 Video

bookmark_border

31. Updates on Teclistamab, Talquetamab, and CARVYKTI | DOCTOR, MD PHD | ASH 2022 Video

bookmark_border

32. Bispecific Antibodies | Joshua Richter, MD | ASH 2022 Video

bookmark_border

33. Prospective evaluation of the biology of aggressive myeloma lesions after induction | ASH 2022 Video

bookmark_border

34. Detecting myeloma with single cell sequencing | Scott Goldsmith, MD | ASH 2022 Video

bookmark_border

35. What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022 Video

bookmark_border

Talquetamab | Ajai Chari, MD | ASH 2022

Last year